Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries and has a highly variable clinical course. The development of new targeted agents such as BTK-inhibitors, PI3-kinase inhibitors and Bcl-2 inhibitors have significantly improved the outcome of CLL patients across the disease spectrum. However, the inclusion of these agents in the treatment pathway means that physicians now have a range of different considerations when managing their CLL patients. Through expert led workshops this meeting will focus on the unmet educational need of clinicians on how to optimally manage patients on the targeted therapies.
After attending this meeting, delegates should be able to: